Wegovy Pill's UAE Debut Is a Distribution Story, Not Just a Market Entry

Novo Nordisk has launched the Wegovy pill, its once-daily oral semaglutide tablet, in the United Arab Emirates (UAE), which became the first country outside of the United States to offer the treatment commercially.¹ The announcement signals the opening move in a sequenced international rollout of an oral GLP-1 that bypasses cold-chain requirements and broadens standard distribution channel eligibility, at a moment when only 2% of the global population with obesity is currently on GLP-1 therapy.²

Why Did Novo Nordisk Choose the UAE as Its First International Market for the Wegovy Pill?

Novo Nordisk's market selection criteria were pointed. In a release, Novo’s executive vice president of International Operations, Emil Kongshøj Larsen, said the launch is an important milestone in the company’s ambition to “expand access to innovative obesity care globally."¹

"As we look to future launches, our approach will be guided by local patient demand, the readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure that can support long-term obesity care,” Larsen said, adding the UAE demonstrated “strong momentum across all of these areas.”¹

“We look forward to bringing Wegovy pill to additional select countries in the coming months," Larsen said.¹

That framework, covering patient demand, HCP readiness, and telehealth infrastructure, resembles a commercialization checklist. The UAE satisfies all three in ways many markets cannot yet claim: a sophisticated private healthcare sector, a growing direct-to-consumer digital health ecosystem, and an obesity burden that underscores the urgency. Novo Nordisk reported that 28% of UAE adults currently live with obesity, with nearly 7.5 million people projected to be living with obesity or overweight in the country by 2035.¹

What Do Oral GLP-1s Mean for Market Expansion?

For all the momentum behind GLP-1s, a market reality looms over any international expansion strategy. According to a market research report on GLP-1 supply and demand dynamics from February, GLP-1 penetration globally remains low, with roughly 7% of patients with diabetes and only 2% of the patients with obesity currently using these medications.² That gap represents commercial opportunity, but it also reflects structural barriers to access.

According to the report, the introduction of oral therapies could boost GLP-1 demand and supply, as they do not require cold chain logistics. The report indicates oral solutions will “help GLP-1s reach areas that otherwise would not be able to support these refrigeration needs.”²

An oral GLP-1 does not just offer patient convenience. It removes friction at nearly every point in the distribution chain. Where injectable GLP-1s have required temperature-controlled logistics, sharps disposal infrastructure, and active patient training, a tablet can move through standard pharmaceutical distribution networks, the kind that already serve high-volume markets in the Middle East, Europe, and beyond.

How Will Novo Nordisk Scale GLP-1s Internationally?

Novo Nordisk noted the Wegovy Pill will be launched in additional “select markets” in the second half of 2026.¹ The company's sequencing, with the US first and the UAE second and broader international markets to follow, reflects a disciplined approach to market readiness assessment that will be closely watched by competitors and distribution partners alike.

Additionally, in May, the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on 7.2 mg injectable Wegovy, recommending EU marketing authorization for single-dose pens and clearing the path for what could be a significant next wave of market entries.³

With obesity affecting one billion people worldwide and GLP-1 utilization rates still in the low single digits globally, the commercial runway is long.^1,2 The question now before pharma supply chain and market access teams is not whether oral GLP-1s will reshape international distribution strategy. It is how fast, and who will be ready.

References

1. Novo Nordisk. Wegovy pill launches in the UAE as Novo Nordisk expands global access to obesity care. Press release. June 3, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916558
2. J.P. Morgan. How Supply and Demand for Weight Loss Drugs is Playing Out in 2026. 2026. https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
3. Novo Nordisk. Wegovy pill (oral semaglutide) recommended by CHMP for approval in the EU. Press release. May 22, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916552